Stockscreener 앱 받기
0.894
0.64%
-0.0058
시간 외 거래:
.85
-0.044
-4.92%
전일 마감가:
$0.8998
열려 있는:
$0.9
하루 거래량:
86,737
Relative Volume:
0.20
시가총액:
$39.93M
수익:
$20.60M
순이익/손실:
$-8.61M
주가수익비율:
-6.4736
EPS:
-0.1381
순현금흐름:
$-5.28M
1주 성능:
+0.42%
1개월 성능:
+10.21%
6개월 성능:
-20.18%
1년 성능:
-16.45%
1일 변동 폭
$0.8842
$0.92
1주일 범위
$0.8535
$0.958
52주 변동 폭
$0.565
$1.31
Scynexis Inc Stock (SCYX) Company Profile
명칭
Scynexis Inc
전화
201-884-5485
주소
1 EVERTRUST PLAZA, JERSEY CITY, NJ
Compare SCYX vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SCYX
Scynexis Inc
|
0.894 | 40.19M | 20.60M | -8.61M | -5.28M | -0.1381 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.11 | 56.96B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.99 | 49.54B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.23 | 45.90B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.44 | 34.48B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
527.00 | 23.24B | 3.18B | 1.33B | 1.04B | 27.90 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-01-22 | 개시 | Guggenheim | Buy |
| 2021-01-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-07-11 | 업그레이드 | Needham | Hold → Buy |
| 2018-06-27 | 개시 | Maxim Group | Buy |
| 2017-10-24 | 개시 | Guggenheim | Buy |
| 2017-07-10 | 개시 | ROTH Capital | Buy |
| 2017-05-09 | 다운그레이드 | Needham | Buy → Hold |
| 2017-03-03 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-10-20 | 개시 | H.C. Wainwright | Buy |
| 2016-10-07 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2016-10-03 | 재개 | Brean Capital | Buy |
| 2016-08-17 | 개시 | Guggenheim | Buy |
| 2016-08-09 | 재확인 | Needham | Buy |
| 2016-08-09 | 업그레이드 | WBB Securities | Speculative Buy → Buy |
| 2016-03-28 | 개시 | Brean Capital | Buy |
| 2015-12-29 | 개시 | WBB Securities | Speculative Buy |
| 2015-11-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2015-06-10 | 개시 | Needham | Buy |
| 2014-05-29 | 개시 | Canaccord Genuity | Buy |
| 2014-05-29 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Scynexis Inc 주식(SCYX)의 최신 뉴스
EBIT per share of SCYNEXIS, Inc. – LSE:0L49 - TradingView
SCYNEXIS (SCYX) Price Target Decreased by 21.43% to 3.74 - MSN
SCYNEXIS, Inc. (SCYX) announces first participants dosed in phase 1 trial of SCY-247 antifungal therapy - MSN
SCYX SEC FilingsScynexis 10-K, 10-Q, 8-K Forms - Stock Titan
SCYNEXIS, Inc. (SCYX) Announces First Participants Dosed in Phase 1 Trial of SCY-247 Antifungal Therapy - Insider Monkey
Brookline Capital cuts SCYNEXIS stock price target on valuation By Investing.com - Investing.com Australia
Brookline Capital cuts SCYNEXIS stock price target on valuation - Investing.com Nigeria
Is SCYNEXIS Inc stock overvalued or fairly priced2025 EndofYear Setup & Growth Focused Investment Plans - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Scynexis Inc earnings beat by $0.12, revenue topped estimates - Investing.com Nigeria
Scynexis Q4 2025 Earnings: Profit of $12.3M, Full-Year 2025 Revenue $20.6MNews and Statistics - IndexBox
Scynexis: Fourth Quarter Financial Results Overview - Bitget
Scynexis: Q4 Earnings Snapshot - marketscreener.com
SCYNEXIS Q4 Earnings Assessment - Benzinga
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update - Bitget
SCYNEXIS Reports Q4 2025 Milestones and Financial Results, Including $24.8 Million Payment from GSK and Advancements in SCY-247 Development - Quiver Quantitative
Scynexis (SCYX) advances SCY-247 antifungal and reshapes GSK ibrexafungerp deal - Stock Titan
SCYX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
SCYNEXIS (SCYX) Projected to Post Quarterly Earnings on Wednesday - Defense World
SCYNEXIS (NASDAQ:SCYX) Stock Price Passes Above 50 Day Moving Average – What’s Next? - Defense World
SCYNEXIS, Inc. (SCYX) Competitors - Meyka
Final SCYX Investor Deadline: Bronstein, Gewirtz & Grossman LLC - GuruFocus
SCYNEXIS (SCYX) Initiates Phase 1 Trial for New Antifungal Thera - GuruFocus
SCYNEXIS doses first patients in SCY-247 IV formulation trial By Investing.com - Investing.com Canada
SCYNEXIS doses first patients in SCY-247 IV formulation trial - Investing.com
SCYNEXIS, Inc. Initiates Phase 1 Trial for Intravenous Antifungal SCY-247 Following FDA Designations - Quiver Quantitative
SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247 - The Manila Times
SCYNEXIS starts dosing trial for antifungal targeting resistant infections - Stock Titan
Can SCYNEXIS Inc. disrupt its industryJuly 2025 Trade Ideas & AI Driven Price Predictions - mfd.ru
Does SCYNEXIS Inc. align with a passive investing strategyTrade Entry Report & Expert-Curated Trade Recommendations - mfd.ru
Short Squeeze: Will SCYNEXIS Inc benefit from rate cutsJuly 2025 PostEarnings & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Kingdon Capital exits Scynexis (SCYX) stake in amended 13G/A filing - Stock Titan
Can SCYNEXIS Inc. expand into new marketsWeekly Risk Report & Consistent Growth Equity Picks - mfd.ru
Market Moves: Is SCYNEXIS Inc backed by strong institutional buyingQuarterly Portfolio Report & AI Forecast Swing Trade Picks - baoquankhu1.vn
Invasive Fungal Infections Market to Witness Upsurge in Growth at a CAGR of 11.4% (in the US) During the Forecast Period (2025-2034) | DelveInsight - The Malaysian Reserve
FOMO Trade: Does SCYNEXIS Inc have pricing powerJuly 2025 Levels & Community Driven Trade Alerts - baoquankhu1.vn
Swing Trade: Is SCYNEXIS Inc backed by strong institutional buyingMarket Performance Summary & Weekly Consistent Profit Watchlists - baoquankhu1.vn
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting - marketscreener.com
Scynexis (SCYX) to Present Data on Advanced Antifungal Drug at K - GuruFocus
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI) - The Manila Times
New antifungal SCY-247 shows potent activity against deadly drug-resistant fungi - stocktitan.net
Companies Like SCYNEXIS (NASDAQ:SCYX) Could Be Quite Risky - Sahm
Aug Macro: Can SCYNEXIS Inc expand into new marketsQuarterly Earnings Summary & Safe Entry Trade Reports - baoquankhu1.vn
JERSEY CITYFDA grants fast track and QIDP designations to SCYNEXIS drug - Investing.com Nigeria
Scynexis (SCYX) Gains FDA Designations for Antifungal Therapy SC - GuruFocus
Scynexis receives FDA qualified infectious disease product and fast track designations for SCY-247 - marketscreener.com
SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247 - The Manila Times
FDA fast-tracks new antifungal aimed at deadly Candida auris infections - Stock Titan
Scynexis Inc (SCYX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.77%
자본화:
|
볼륨(24시간):